Calidi BiotherapeuticsCLDI -5.88%12 Debt-to-Equity is 0.46 as of Mar. 2026. GuruFocus rates CLDI with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 966 Biotechnology companies, Calidi Biotherapeutics ranks worse than 73.19% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Calidi Biotherapeutics's Debt-to-Equity or its related term are showing as below:
CLDI'
s Debt-to-Equity Range Over the Past 10 Years
Min: -8.91 Med: -0.12 Max: 4.59
Current: 0.46
During the past 6 years, the highest Debt-to-Equity Ratio of Calidi Biotherapeutics was 4.59. The lowest was -8.91. And the median was -0.12.
CLDI's Debt-to-Equity is ranked worse than 73.19% of 966
companies
in the Biotechnology industry
Industry Median: 0.16
vs CLDI: 0.46
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Calidi Biotherapeutics Debt-to-Equity Related Terms
Calidi Biotherapeutics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Calidi Biotherapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLDI vs DCOY, CDT, ACUT: Debt-to-Equity Comparison
For the Biotechnology subindustry, Calidi Biotherapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Calidi Biotherapeutics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Calidi Biotherapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Calidi Biotherapeutics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Calidi Biotherapeutics (CLDI) has a Debt-to-Equity of 0.46 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Calidi Biotherapeutics and its competitors. According to the industry distribution chart, Calidi Biotherapeutics ranks #707 out of 966 companies in the Biotechnology industry, placing it in the top 73.2%.
Is Calidi Biotherapeutics' Debt-to-Equity too high?
Calidi Biotherapeutics' current Debt-to-Equity is 0.46. The Biotechnology industry median Debt-to-Equity is 0.16. Calidi Biotherapeutics' value of 0.46 is 187.5% above this industry median. Based on the distribution chart, Calidi Biotherapeutics ranks #707 out of 966 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Calidi Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Calidi Biotherapeutics' Debt-to-Equity compare to DCOY and CDT?
According to the Biotechnology industry distribution chart, Calidi Biotherapeutics ranks #707 out of 966 companies for Debt-to-Equity. This places Calidi Biotherapeutics in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Calidi Biotherapeutics' value of 0.46 is 187.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Calidi Biotherapeutics's current Debt-to-Equity of 0.46 is 187.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Calidi Biotherapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Calidi Biotherapeutics's current Debt-to-Equity is 0.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Calidi Biotherapeutics stock overvalued right now?
Calidi Biotherapeutics (CLDI) has a current Debt-to-Equity of 0.46. The current Debt-to-Equity is 0.46 and 187.5% above the Biotechnology industry median of 0.16. Calidi Biotherapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Calidi Biotherapeutics (CLDI), the current Debt-to-Equity is 0.46 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
12GF Score
Get the complete analysis for CLDI
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLDI has been successfully added to your 
